Summary
The properties of trimethoprim (TM), reviewed here, show it to be an excellent antimicrobial agent in its own right. However, with very few exceptions, TM has been made available clinically only in combination with a sulphonamide, usually sulphamethoxazole (SMX). We present evidence to suggest that the decision so to restrict the availability of TM was mistaken. Synergy between TM and SMX can be shown clearly in vitro, but there is no evidence from clinical trials that it plays a significant therapeutic role in urinary infections. Also, there is no evidence that combining the two antibiotics suppresses the emergence of resistance. Recently, sulphonamides other than SMX have been proposed as partners for TM, mainly on pharmacokinetic grounds. Compounds other than sulphonamides may also be logical partners for TM: we have made extensive studies on TM + rifampicin, for instance, and have obtained excellent results in certain clearly-defined patient groups. Only clinical trials of these new combinations will reveal whether they are superior to TM/SMX. There is already sufficient evidence to suggest that TM alone will be as effective as, and more acceptable than, TM/SMX. We propose that further large-scale clinical trials with TM alone be carried out, both to treat acute urinary infections and in prophylaxis.
Zusammenfassung
Die hier besprochenen Eigenschaften von Trimethoprim (TM) zeigen, daß es für sich allein ein vorzügliches antimikrobielles Mittel ist. Jedoch ist TM mit sehr wenigen Ausnahmen klinisch nur in Verbindung mit einem Sulfonamid, für gewöhnlich Sulfamethoxazol (SMX) zur Verfügung gestellt worden. Wir stellen Faktoren vor, aus denen geschlossen werden kann, daß es falsch war, die Verfügbarkeit von TM so einzuschränken. Der Synergismus zwischen TM und SMX kann in vitro eindeutig nachgewiesen werden, doch gibt es aus klinischen Untersuchungen keine Beweise dafür, daß er bei Harnwegsinfektionen eine wesentliche therapeutische Rolle spielt. Auch kann nicht bewiesen werden, daß die Kombination der beiden Antibiotika die Resistenzentwicklung vermindert. In jüngerer Zeit wurden vorwiegend aus pharmakokinetischen Gründen andere Sulfonamide als SMX als Partner für TM vorgeschlagen. Außer Sulfonamiden können auch andere Verbindungen sinnvolle Partner für TM sein. Wir haben beispielsweise ausgedehnte Untersuchungen an TM + Rifampicin durchgeführt und bei bestimmten klar umrissenen Patientengruppen ausgezeichnete Ergebnisse erzielt. Nur klinische Untersuchungen über diese neuen Kombinationen werden klären, ob sie dem TM/SMX überlegen sind. Es gibt bereits genügend Belege für die Annahme, daß TM allein ebenso wirksam sein wird wie TM/SMX und zugleich zufriedenstellender. Wir machen den Vorschlag, daß weitere umfangreiche klinische Versuche mit TM allein zur Behandlung von akuten Harnwegsinfektionen und zur Prophylaxe durchgeführt werden.
Similar content being viewed by others
Literature
Hitchings, G. H. Species differences among dihydrofolate reductases as a basis for chemotherapy. Postgrad. Med. J. 45 Suppl. (1969) 7–10.
Waterworth, P. M. Practical aspects of testing sensitivity to trimethoprim and sulphonamide. Postgrad. Med. J. 45 Suppl. (1969) 21–27.
McAllister, T. A., Alexander, J. G., Dulake, C., Percival, A., Boyce, J. M. H., Wormald, P. J. Multicentric study of sensitivities of urinary tract pathogens. Postgrad. Med. J. 47 Suppl. (1971) 7–14.
Lewis, E. L., Lacey, R. W. Present significance of resistance to trimethoprim and sulphonamides in coliforms,Staphylococcus aureus, andStreptococcus faecalis. J. Clin. Pathol., 26 (1973) 175–180.
Fruensgaard, K., Korner, B. Alterations in the sensitivity pattern after use of trimethoprim/sulfamethoxazole für two years in the treatment of urinary tract infections. Chemotherapy 20 (1974) 97–101.
Ortel, S. Trimethoprim resistance of pathogenic organisms previous to common clinical use of sulprim®. Proc. 9th Int. Congress Chemoth. 6 (1974) 353–358.
Grüneberg, R. N. Susceptibility of urinary pathogens to various antimicrobial substances: a four-year study. J. Clin. Pathol. 29 (1976) 292–295.
Grey, D., Hamilton-Miller, J. M. T., Brumfitt, W.: Incidence and mechanisms of resistance to trimethoprim in clinically isolated Gram-negative bacteria. Chemotherapy (1979) (in press).
Grey, D., Hamilton-Miller, J. M. T. Trimethoprim-resistant bacteria: cross-resistance patterns. Microbios 19 (1977) 45–54.
Jobanputra, R. S., Datta, N. Trimethoprim R-factors in enterobacteria from clinical specimens. J. Med. Microbiol. 7 (1974) 169–177.
Amyes, S. G. B., Smith, J. T. The purification and properties of the trimethoprim-resistant dihydrofolate reductase mediated by the R-factor, R 388. Eur. J. Biochem. 61 (1976) 597–603.
Maskell, R., Okubadejo, O. A., Payne, R. H., Pead, L. Human infections with thymine-requiring bacteria. J. Med. Microbiol. 11 (1978) 33–45.
Smith, H. W., Tucker, J. F. The virulence of trimethoprim-resistant thymine-requiring strains ofSalmonella. J. Hyg. (Cambridge) 76 (1976) 97–108.
Amyes, S. G. B., Smith, J. T. Thymineless mutants and their resistance to trimethoprim. J. Antimicr. Chemother. 1 (1975) 85–89.
Schwartz, D. E., Rieder, J. Pharmacokinetics of sulfamethoxazole + trimethoprim in man and their distribution in the rat. Chemotherapy 15 (1970) 337–355.
Nolte, H., Buttner, H. Pharmacokinetics of trimethoprim and its combination with sulfamethoxazole in man after single and chronic oral administration. Chemotherapy 18 (1973) 274–284.
Schwartz, D. E., Vetter, W., Englert, G. Trimethoprim metabolites in rat, dog and man: Qualitative and quantitative studies. Arzneim.-Forsch. 20 (1970) 1867–1871.
Brumfitt, W., Faiers, M. C., Pursell, R. E., Reeves, D. S., Turnbull, A. R. Bacteriological, pharmacological and clinical studies with trimethoprim-sulphonamide combinations, with particular reference to the treatment of urinary infections. Postgrad. Med. J. 45 Suppl. (1969) 56–61.
Kaplan, S. A., Weinfeld, R. E., Abruzzo, C. W., McFaden, K., Jack, M. L., Weissman, L. Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man. J. Infect. Dis. Suppl. 128 (1973) S547-S555.
Welling, P. G., Craig, W. A., Amidon, G. L., Kunin, C. M. Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. J. Infect. Dis. Suppl. 128 (1973) S556-S566.
Bach, M. C., Gold, O., Finland, M. Absorption and urinary excretion of trimethoprim, sulfamethoxazole, and trimethoprim-sulfamethoxazole: Results with single doses in normal young adults and preliminary observations during therapy with trimethoprim-sulfamethoxazole. J. Infect. Dis. 128 (1973) S584-S598.
Raeburn, J. A. A method for studying antibiotic concentrations in inflammatory exudate. J. Clin. Pathol. 24 (1971) 633–635.
Symposium: Antibiotic tissue concentration, determination and significance. Infection 4 Suppl. (1976) S79-S170.
Gillett, A. P., Wise, R. Penetration of four cephalosporins into tissue fluid in man. Lancet 1 (1978) 962–964.
Rieder, J., Schwartz, D. E., Fernex, M., Bergan, T., Brodwall, E. K., Blumberg, A., Cottier, P., Scheitlin, W. Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function. Antibiot. Chemother. 18 (1974) 148–198.
Kremers, P., Duvivier, J., Heusghem, C. Pharmacokinetic studies of co-trimoxazole in man after single and repeated doses. J. Clin. Pharmacol. 14 (1974) 112–117.
Grey, D., Hamilton-Miller, J. M. T., Brumfitt, W.: Combined action of sulphamethoxazole and trimethoprim against clinically-isolated sulphonamide-resistant bacteria. Chemotherapy (1979) (in press).
Stokes, A., Lacey, R. W. Effect of thymidine on activity of trimethoprim and sulphamethoxazole. J. Clin. Pathol. 31 (1978) 165–171.
Brumfitt, W., Pursell, R. Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole, and trimethoprim in treatment of urinary infection. Br. Med. J. 2 (1972) 673–676.
Hoigné, R., Muller, U., Schneider, H. R. A comparison of chemotherapy in patients with urinary tract infections using trimethoprim alone and in combination with sulfamethoxazole (Gantanol). Proc. 6th Int. Congr. Chemoth. 1 (1970) 971–974.
Böhni, E. Co-trimoxazole in sulfonamide-resistant infections. Proc. 8th Int. Congr. Chemoth. 2 (1974) 204–210.
Acar, J. F., Goldstein, F., Chabbert, Y. A. Synergistic activity of trimethoprim-sulfamethoxazole on Gram-negative bacilli: observations in vitro and in vivo. J. Infect. Dis. Suppl. 128 (1973) S470-S477.
Hamilton-Miller, J. M. T., Brumfitt, W. Clinical aspects of in vitro antimicrobial synergism: In:Mouton, R. P., Brumfitt, W., Hamilton-Miller, J. M. T. (ed): The rational choice of antibacterial agents. Bohn, Scheltema & Holkema, Utrecht, 1977, p89–100.
Lewis, E. L., Anderson, J. D., Lacey, R. W. A reappraisal of the antibacterial action of cotrimoxazole in vitro. J. Clin. Pathol. 27 (1974) 87–91.
Anderson, J. D., Lacey, R. W., Lewis, E. L., Sellin, M. A. Failure to demonstrate an advantage in combining sulphamethoxazole with trimethoprim in an experimental model of urinary infection. J. Clin. Pathol. 27 (1974) 619–622.
Knothe, H. The effect of a combined preparation of trimethoprim and sulphamethoxazole following short-term and long term administration on the flora of the human gut. Chemotherapy 18 (1973) 285–296.
Toivanen, A., Kasanen, A., Sundquist, H., Toivanen, P. Effect of trimethoprim on the occurrence of drug-resistant coliform bacteria in the faecal flora. Chemotherapy 22 (1976) 97–103.
Symposium: Nevin® — Supristol®. Arzneim.-Forsch. 26 (1976) 595–684.
Bergan, T., Vik-Mo, H., Anstad, U. Kinetics of a sulfadiazine-trimethoprim combination. Clin. Pharmacol. Therapeut. 22 (1977) 211–224.
Nabert-Bock, V. G., Grims, H. Bakteriologie des Chemotherapeutikums Sulfametrol-Trimethoprim. Vergleich mit Co-trimoxazol. Arzneim.-Forsch. 27 (1977) 1109–1117.
Brumfitt, W.: Rifampicin synergism — the use of rifampicin in combination with trimethoprim and other antibiotics. Symposium on Anonymous Mycobacteria and Use of Rifampicin in the Treatment of Infectious Diseases, Hook, 1978.
Sourander, L. B., Werner, G. E. Efficacy and tolerance of sulphonamide-trimethoprim combinations in geriatric patients with bacteriuria. Proc. 5th Int. Congr. Chemoth. 5 (1967) 199–211.
Koch, U. J., Schumann, K. P., Kuchler, R., Kewitz, H. Efficacy of trimethoprim, sulfamethoxazole and the combination of both in acute urinary tract infection. Chemotherapy 19 (1973) 314–321.
Kasanen, A., Toivanen, P., Sourander, L., Kaarsalo, E., Anataa, S. Trimethoprim in the treatment and long-term control of urinary tract infection. Scand. J. Infect. Dis. 6 (1974) 91–96.
Kasanen, A., Kaarsalo, E., Hiltunen, R., Soini, V. Comparision of long-term, low-dosage nitrofurantoin, methenamine hippurate, trimethoprim and trimethoprim-sulphamethoxazole in the control of recurrent urinary tract infection. Ann. Clin. Res. 6 (1974) 285–289.
Männistö, P. T. Comparison of oxolinic acid, trimethoprim and trimethoprim-sulphamethoxazole in the treatment and long-term control of urinary tract infection. Curr. Ther. Res. 20 (1976) 645–654.
Kunin, C. M., Craig, W. A., Uehling, D. T. Trimethoprim therapy for urinary tract infection. J. Am. Med. Assoc. 239 (1978) 2588–2590.
Brumfitt, W., Hamilton-Miller, J. M. T., Grey, D. Trimethoprim-resistant coliforms. Lancet 2 (1977) 926.
O'Grady, F., Fry, I. K., McSherry, A., Cattell, W. R. Long-term treatment of persistent or recurrent urinary tract infection with trimethoprim-sulfamethoxazole. J. Inf. Dis. 128 (1973) S652-S656.
Towner, K. J., Pearson, N. J., Cattell, W. R., O'Grady, F. Chromosomal resistance to trimethoprim. Lancet 1 (1978) 1371.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brumfitt, W., Hamilton-Miller, J.M.T. General survey of trimethoprim combinations in the treatment of urinary tract infections. Infection 7 (Suppl 4), S388–S393 (1979). https://doi.org/10.1007/BF01639018
Issue Date:
DOI: https://doi.org/10.1007/BF01639018